BUY Laurus Labs Ltd — Manas Jaiswal
byManas JaiswalHorizon: NA (inferred Swing (≤2wk))8 May 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Laurus Labs Ltd Reports Very Positive Quarterly Financial Performance Amid Strong Long-Term Returns
NewsGoogle News·4 May · 1w ago
Laurus Labs announced its Q4 and Full Year FY26 financial results, reporting revenues of ₹6,813 Cr and EBITDA of ₹1,826 Cr, with a 26.8% margin. The company highlighted strong revenue growth and expan
NSE · Press Release·30 Apr · 2w ago
1 advisor has an active short-term BUY call on this stock
Advisor consensus · adjacent horizon·2 Apr · 1mo ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Laurus Labs
- BUY — Sachin Janardan Sarvade, IDBI Capital Markets and Securities16 Oct 2026 · ~3 months · target ₹2,400 · Active
- BUY — Shivangi Sarda, Motilal Oswal16 Oct 2026 · ~2 weeks · target ₹2,150 · SL hit
- BUY — Nuvama Wealth16 Oct 2026 · ~1 year · target ₹2,520 · Active
- BUY — Shivangi Sarda, Motilal Oswal13 Oct 2026 · ~3 months · target ₹2,100 · SL hit
- BUY — Ansh Jogendra Bhilwar13 Oct 2026 · ~2 weeks · target ₹2,155 · SL hit
More from Manas Jaiswal
- BUY Ajanta Pharma23 Oct 2026 · Same day · target ₹3,425 · SL hit
- BUY Torrent Pharmaceuticals23 Oct 2026 · Same day · target ₹4,725 · SL hit
- BUY SAGILITY23 Oct 2026 · ~2 weeks · target ₹50 · SL hit
- BUY Zydus Lifesciences22 Oct 2026 · ~3 months · target ₹1,160 · SL hit
- BUY IPCA Laboratories22 Oct 2026 · ~2 weeks · target ₹2,000 · Active

